No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
TNFRSF8 positive	Hodgkin Lymphoma	TNFRSF8 positive	Hodgkin Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
TNFRSF8 positive	Cutaneous T-cell Lymphoma	TNFRSF8 positive	Cutaneous T-cell Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
TNFRSF8 expression	Peripheral T-cell Lymphoma	TNFRSF8 expression	Peripheral T-cell Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	rituximab + lenalidomide + brentuximab vedotin Sensitive: A1 - Approval rituximab + lenalidomide + brentuximab vedotin Sensitive : A1	rituximab + lenalidomide + brentuximab vedotin Sensitive: A1 - Approval rituximab + lenalidomide + brentuximab vedotin Sensitive : A1
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	nivolumab + brentuximab vedotin Sensitive: A2 - Guideline nivolumab + brentuximab vedotin Sensitive : A2	nivolumab + brentuximab vedotin Sensitive: A2 - Guideline nivolumab + brentuximab vedotin Sensitive : A2
TNFRSF8 positive	Diffuse Large B Cell Lymphoma	TNFRSF8 positive	Diffuse Large B Cell Lymphoma	brentuximab vedotin Sensitive: A2 - Guideline brentuximab vedotin Sensitive : A2	brentuximab vedotin Sensitive: A2 - Guideline brentuximab vedotin Sensitive : A2
TNFRSF8 positive	Peripheral T-cell Lymphoma	TNFRSF8 positive	Peripheral T-cell Lymphoma	brentuximab vedotin Sensitive: A2 - Guideline brentuximab vedotin Sensitive : A2	brentuximab vedotin Sensitive: A2 - Guideline brentuximab vedotin Sensitive : A2
ALK positive	T Cell Non-Hodgkin Lymphoma	ALK positive	T Cell Non-Hodgkin Lymphoma	brentuximab vedotin Sensitive: B - Late Trials brentuximab vedotin Sensitive : B	brentuximab vedotin Sensitive: B - Late Trials brentuximab vedotin Sensitive : B
ALK positive	Non-Hodgkin’s Lymphoma	ALK positive	Non-Hodgkin’s Lymphoma	brentuximab vedotin Sensitive: B - Late Trials brentuximab vedotin Sensitive : B	brentuximab vedotin Sensitive: B - Late Trials brentuximab vedotin Sensitive : B

CD30-targeted antibody-drug conjugate

CD30-targeted antibody-drug conjugate

Associations(35)

Associations
(35)